NASDAQ$GBIO

Generation Bio Co · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Generation Bio reported Q1 2025 revenue of $100.0K, a net loss of $14.8M, diluted EPS of $-0.22.

For Q1 2025, Generation Bio reported Revenue was $100.0K, net loss was $14.8M, diluted EPS was $-0.22. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $100.0K for Q1 2025.
  • Net loss $14.8M.
  • Diluted EPS $-0.22.

Headline financials

Total Revenue

$8.72M

Previous: $4.06M+114.9%
EPS (adj)

-$0.22

Previous: -$1.12+80.4%
Weighted average common shares outstanding

67.0M

Previous: 66.4M+0.9%
Research and development expenses

$15.4M

Previous: $14.3M+7.1%
General and administrative expenses

$8.83M

Previous: $10.4M-15.3%
Loss on lease termination

$1.14M

Previous: $56.9M-98.0%
Other income and interest income, net

$1.8M

Previous: $3.09M-41.7%
Capital Expenditures

-$246K

Previous: -$1.92M+87.2%
Net Income

-$14.8M

Previous: -$74.5M+80.1%
Operating Income

-$16.6M

Previous: -$77.6M+78.6%

Revenue & EPS history

Generation Bio · Revenue · Quarterly

$8.72M

Q1 2025+114.9%vs Q1 2024
Beat estimate in 7 of 10 quarters(70%)
ActualEstimate

Revenue by segment

Generation Bio · $2.15M total across 1 segment · Q3 2023

  • Collaboration revenue
    $2.15M

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.

Tailwinds

  • Pipeline readouts and partnership economics.
  • Cash balance supports near-term development plans.

Headwinds

  • Operating losses and trial risk until commercialization.
  • Financing markets and competition affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+3.8%

Avg return

Earnings day

+5.9%

Avg return

5 days after

+8.6%

Avg return

30 days after

43%

10 / 23 earnings

Positive

+61.7%

Q2 2025

Best reaction

-19.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025-3.3%+11.0%+2.7%
Q2 2025+61.7%+62.0%+46.9%
Q1 2025+4.5%+0.4%+4.0%
Q4 2024-3.7%-14.3%-9.5%
Q3 2024+8.7%-0.5%-40.8%
Q2 2024-2.0%-3.7%-10.2%
Q1 2024+18.4%+16.4%+1.9%
Q4 2023+3.1%+11.5%+39.4%
Q3 2023-1.7%+7.7%+46.2%
Q2 2023-5.3%-7.0%+6.8%
Q1 2023-5.0%-2.7%+0.4%
Q4 2022-8.4%-10.0%+15.5%
Q3 2022+12.2%
Q2 2022+7.7%
Q1 2022-19.7%
Q4 2021+21.1%
Q3 2021-1.5%
Q2 2021-6.2%
Q1 2021+0.3%
Q4 2020-0.9%
Q3 2020+8.5%
Q4 2019-0.5%
Q2 2020-0.5%
Q1 2020
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro